Brokerages Set Pulmonx Corporation (NASDAQ:LUNG) PT at $5.58

Shares of Pulmonx Corporation (NASDAQ:LUNG) have been assigned an average recommendation of “Hold” from the seven analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $5.5833.

Several brokerages recently commented on LUNG. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research note on Thursday, April 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a report on Monday, July 13th.

Hedge Funds Weigh In On Pulmonx

Institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Pulmonx during the first quarter valued at about $26,000. Cerity Partners LLC bought a new stake in shares of Pulmonx during the fourth quarter worth about $27,000. FNY Investment Advisers LLC acquired a new position in shares of Pulmonx in the third quarter valued at approximately $29,000. Opal Capital LLC acquired a new position in shares of Pulmonx in the fourth quarter valued at approximately $29,000. Finally, Regatta Capital Group LLC bought a new position in Pulmonx in the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Stock Performance

Pulmonx stock opened at $1.40 on Thursday. Pulmonx has a 12-month low of $1.13 and a 12-month high of $3.88. The company has a quick ratio of 4.04, a current ratio of 4.91 and a debt-to-equity ratio of 0.81. The business’s 50-day moving average price is $1.43 and its two-hundred day moving average price is $1.53. The stock has a market cap of $59.13 million, a PE ratio of -1.08 and a beta of 0.30.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, April 29th. The company reported ($0.33) EPS for the quarter, hitting analysts’ consensus estimates of ($0.33). Pulmonx had a negative net margin of 60.09% and a negative return on equity of 92.94%. The firm had revenue of $20.59 million during the quarter, compared to analysts’ expectations of $20.43 million. As a group, analysts expect that Pulmonx will post -1.13 earnings per share for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.